A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).Jonathan W. Riess, Karen Kelly, Liza C. Villaruz et al.|Journal of Clinical Oncology|2021Cited by 10
1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900AJonathan W. Riess, Karen Kelly, Jieling Miao et al.|Annals of Oncology|2024Cited by 2